Amgen v. Sanofi: The More a Patent Claims, the More It Must Enable Video

Summary

This video discusses the enablement requirement of 35 U.S.C. § 112(a) as it relates to biotechnology and specifically antibody claims, addressed by the Supreme Court in Amgen Inc. v. Sanofi, 143 S. Ct. 1243 (2023).